Concert Pharmaceuticals Reports Year Ended 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St futures flat after tech rout; Iran tensions, retail earnings in focus
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Target raises full-year sales forecast amid ongoing turnaround drive
- Global bond rout pauses as sovereign yields back off multi-decade highs
- Lowe's slashes full-year sales outlook amid DIY spending pressure
- Tech selloff weighs down Wall Street as bond yields climb
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
Concert Pharma (CNCE) Tops Q4 EPS by 7c
March 6, 2017 7:19 AM ESTConcert Pharma (NASDAQ: CNCE) reported Q4 EPS of ($0.54), $0.07 better than the analyst estimate of ($0.61).
For earnings history and earnings-related data on Concert Pharma (CNCE) click here.
... More